Ascletis Pharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2.03	1.28	56.6	54.09	76.88
Revenue Growth (YoY)	58.07%	-97.73%	4.63%	-29.64%	119.64%
Cost of Revenue	1.5	0.55	30.61	78.78	37.7
Gross Profit	0.53	0.74	25.99	-24.69	39.17
Selling, General & Admin	75.23	101.74	116.02	52.18	50.82
Research & Development	409.05	302.39	216.78	267.1	213.32
Other Operating Expenses	0.77	1.23	2.14	4.64	5.5
Operating Expenses	485.06	405.37	334.94	323.93	269.64
Operating Income	-484.53	-404.63	-308.95	-348.62	-230.47
Interest Expense	-0.16	-0.24	-0.14	-0.16	-0.13
Interest & Investment Income	-	92.24	99.28	47.48	24.99
Earnings From Equity Investments	-	-5.27	-20.28	-22.89	-17.88
Currency Exchange Gain (Loss)	-	4.15	9.7	60.18	-16.44
Other Non Operating Income (Expenses)	125.32	21.16	6.7	4.35	40.9
EBT Excluding Unusual Items	-359.37	-292.61	-213.69	-259.65	-199.02
Gain (Loss) on Sale of Investments	-	2.25	68.97	-	-
Asset Writedown	-	-10.58	-	-55.19	-
Pretax Income	-359.37	-300.94	-144.72	-314.84	-199.02
Income Tax Expense	0.51	-	-	-	-
Earnings From Continuing Operations	-359.88	-300.94	-144.72	-314.84	-199.02
Net Income	-359.88	-300.94	-144.72	-314.84	-199.02
Net Income to Common	-359.88	-300.94	-144.72	-314.84	-199.02
Shares Outstanding (Basic)	972	1,002	1,074	1,087	1,098
Shares Outstanding (Diluted)	972	1,002	1,074	1,087	1,098
Shares Change (YoY)	-2.92%	-6.75%	-1.19%	-0.96%	5.53%
EPS (Basic)	-0.37	-0.30	-0.13	-0.29	-0.18
EPS (Diluted)	-0.37	-0.30	-0.13	-0.29	-0.18
Free Cash Flow	-416.78	-343.67	-230.01	-209.53	-151.9
Free Cash Flow Per Share	-0.43	-0.34	-0.21	-0.19	-0.14
Gross Margin	25.99%	57.29%	45.92%	-45.65%	50.96%
Operating Margin	-23892.11%	-31538.04%	-545.88%	-644.51%	-299.79%
Profit Margin	-17745.56%	-23455.65%	-255.70%	-582.07%	-258.88%
Free Cash Flow Margin	-20551.08%	-26786.75%	-406.40%	-387.38%	-197.59%
EBITDA	-470.35	-390.45	-294.89	-322.49	-204.83
EBITDA Margin	-	-	-	-	-266.45%
D&A For EBITDA	14.18	14.18	14.05	26.13	25.64
EBIT	-484.53	-404.63	-308.95	-348.62	-230.47
EBIT Margin	-	-	-	-	-299.79%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.